NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults

Phase 1

Not yet recruiting

Conditions: West Nile Viral Infection

Interventions: Biological: HydroVax-001B WNV
Other: Placebo
Other: Sodium Chloride, 0.9%

First Posted Date: 2024-12-20

Last Posted Date: 2025-01-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 30

Registration Number: NCT06745921

First-in-Human PfSPZ-LARC2 Vaccination/CHMI

Phase 1

Not yet recruiting

Conditions: Malaria

Interventions: Biological: PfSPZ Vaccine
Biological: PfSPZ (7G8) Challenge
Other: Sodium Chloride, 0.9%

First Posted Date: 2024-12-16

Last Posted Date: 2025-01-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 40

Registration Number: NCT06735209

Locations: 🇺🇸
University of Washington - Harborview Medical Center - Center for AIDS and STD, Seattle, Washington, United States

A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up

Recruiting

Conditions: Allergy, Sinus Disorders, Atopic Diseases, Asthma, Allergic Rhinitis, Atopic Dermatitis, EoE, Drug a

First Posted Date: 2024-12-13

Last Posted Date: 2025-01-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10000

Registration Number: NCT06732414

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients

Phase 2

Recruiting

Conditions: Autoimmune Lymphoproliferative Syndrome

Interventions: Drug: Soquelitinib

First Posted Date: 2024-12-12

Last Posted Date: 2025-01-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 15

Registration Number: NCT06730126

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Aviptidil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

Phase 3

Completed

Conditions: Covid19

Interventions: Biological: Aviptidil
Biological: Aviptidil Placebo
Drug: Corticosteroid

First Posted Date: 2024-12-11

Last Posted Date: 2024-12-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 471

Registration Number: NCT06729606

Locations: 🇺🇸
Banner University Medical Center Tucson (Site 206-004), 1625 N. Campbell Avenue, Tucson, Arizona, United States
🇺🇸
UCSF Fresno (Site 203-005), 155 N. Fresno Street, Fresno, California, United States
🇺🇸
VA Loma Linda Healthcare System (Site 074-017), 11201 Benton Street, Loma Linda, California, United States

and more 37 locations

Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

Phase 3

Completed

Conditions: Covid19

Interventions: Biological: Remdesivir Placebo
Biological: Remdesivir
Drug: Corticosteroid

First Posted Date: 2024-12-11

Last Posted Date: 2024-12-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 87

Registration Number: NCT06729593

Locations: 🇺🇸
UCSF Medical Center (Site 203-001), Moffit-Long Hospital, 505 Parnassus Ave., San Francisco, California, United States
🇺🇸
Stanford University Hospital & Clinics (Site 203-003), 300 Pasteur Dr., Stanford, California, United States
🇺🇸
Banner University Medical Center Tucson (Site 206-004), 1625 N. Campbell Avenue, Tucson, Arizona, United States

and more 37 locations

Tecovirimat for Treatment of Monkeypox Virus - Study Extension Providing Standard of Care Only

Recruiting

Conditions: Mpox (Monkeypox)

Interventions: Other: Standard of Care (SOC)
Drug: Tecovirimat Oral Capsule [Tpoxx]

First Posted Date: 2024-12-06

Last Posted Date: 2024-12-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 400

Registration Number: NCT06721585

Locations: 🇨🇩
L'Hôpital Général de Référence de Kole, Kole, Congo, The Democratic Republic of the
🇨🇩
L'Hôpital Général de Référence de Tunda, Tunda, Congo, The Democratic Republic of the

Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)

Phase 4

Not yet recruiting

Conditions: Bacterial Infection

Interventions: Drug: Iohexol

First Posted Date: 2024-11-29

Last Posted Date: 2024-12-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 150

Registration Number: NCT06709521

Locations: 🇺🇸
Torrance Memorial Medical Center, Torrance, California, United States
🇺🇸
Harbor UCLA Medical Center - Medicine - Infectious Diseases, Torrance, California, United States
🇺🇸
Henry Ford Health System - Henry Ford Hospital, Detroit, Michigan, United States

and more 3 locations

Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

Phase 2

Not yet recruiting

Conditions: Major Depressive Disorder
Mild Neurocognitive Disorder
HIV

Interventions: Drug: Pramipexole ER
Drug: Escitalopram

First Posted Date: 2024-11-26

Last Posted Date: 2024-11-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 186

Registration Number: NCT06705478

Locations: 🇺🇸
Alabama CRS, Birmingham, Alabama, United States
🇺🇸
University of California, Los Angeles CARE Center CRS, Los Angeles, California, United States
🇺🇸
UCSD Antiviral Research Center CRS, San Diego, California, United States

and more 36 locations

Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults

Phase 2

Not yet recruiting

Conditions: Escherichia Infection

Interventions: Other: B7A (ETEC challenge strain)
Biological: CssBA
Other: Placebo
Biological: dmLT

First Posted Date: 2024-11-18

Last Posted Date: 2025-01-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 72

Registration Number: NCT06692907

Locations: 🇺🇸
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States
🇺🇸
Cincinnati Children's Hospital Medical Center Vaccine Research Center, Cincinnati, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy